← Leaderboards
Paula M Fracasso
Washington University
$1,120,427
Attributed
$1,120,427
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $336.3K · FY2007–09$500K$375K$250K$125K$0
'07
'08
'09
Funding mix
By agency
NIH$1,120,427 · 3
By mechanism
R21$955,572 · 2
U54$164,855 · 1
Top collaborators
No co-investigators on record.
Most similar at Washington University
Same institution · by research overlap
- Helen M Piwnica-Worms$9,529,923
- Lee Ratner$26,026,037
- Nancy L Bartlett$8,628,353
- Mai Xu$132,240
Others in their field
Top investigators on “Base”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$613,567,095
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Larry Arthur$521,411,998
- Leonard Freedman · Leidos Biomedical Research, Inc.$515,995,429
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$507,042,060
Research focus
BaseTumorProgramsClinical TrialsWomanComplementClinical Trial Phase IiComputer Assisted Medical Decision MakingClinical ProtocolsChes1 GeneAnthracyclinesAkt1 Gene3-Phosphoinositide Dependent Protein Kinase-1Clinical ResearchCancer Therapy Evaluation ProgramCdc25a GeneBehavioral /Social Science Research TagBiological MarkersBiopsy SpecimenCell LineAnthracycline AntibioticsClassificationBreast7-Hydroxystaurosporine
Grant awards (7)
Education and Dissemination of Nanomedicine in Cancer Core (EDNIC)$97,811
U54 · FY2009 · CA · contact PI
An Exploratory Study of UCN-01 and Irinotecan in Advanced Triple Negative Breast$269,233
R21 · FY2008 · CA · contact PI
Education and Dissemination of Nanomedicine in Cancer Core (EDNIC)$67,044
U54 · FY2008 · CA · contact PI
An Exploratory Study of UCN-01 and Irinotecan in Advanced Triple Negative Breast$278,385
R21 · FY2007 · CA · contact PI
Overcoming Barriers to Early Phase Clinical Trials$206,619
R21 · FY2004 · CA
Overcoming Barriers to Early Phase Clinical Trials$76,570
R21 · FY2004 · CA
Overcoming Barriers to Early Phase Clinical Trials$124,765
R21 · FY2003 · CA